Looking Back: Ovarian Cancer in 2017

Video

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on exciting developments in the ovarian cancer field from 2017. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes these drugs have great potential in ovarian cancer treatment.

Recent Videos
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
gynecologic system with cancerous tumor

Sacituzumab Tirumotecan Shows Promise in Pretreated Gynecologic Cancer

Ashley Chan
November 18th 2024
Article

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

clinician in white coat holding a board that says "cervical cancer"

Adding Cancer Vaccine to Avelumab Doesn’t Boost PFS in Gynecologic Cancer

Russ Conroy
October 16th 2024
Article

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

gynecologic system

WHO Updates Cervical Cancer Prevention Guidelines

Chris Ryan
October 8th 2024
Article

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

gynecologic cancer

Dato-DXd Seems Safe, Efficacious in Advanced Gynecologic Cancers

Jason M. Broderick
September 18th 2024
Article

Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.

© 2024 MJH Life Sciences

All rights reserved.